Morishima et al., 1980 - Google Patents

Local immunity in mumps meningitis

Morishima et al., 1980

Document ID
3174962525848374794
Author
Morishima T
Miyazu M
Ozaki T
Isomura S
Suzuki S
Publication year
Publication venue
American journal of diseases of children

External Links

Snippet

• Titers of antibodies to mumps and measles virus and interferon activity were measured in sera and CSF obtained from 15 children with mumps meningitis. Antibody to mumps virus was found in 11 of 15 CSF samples. Evaluation of the CSF-serum ratio for antibodies to both …
Continue reading at jamanetwork.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses

Similar Documents

Publication Publication Date Title
Friedman et al. The role of antibody, delayed hypersensitivity, and interferon production in recovery of guinea pigs from primary infection with vaccinia virus
Hagiwara et al. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection
Vignaux et al. Differential effects of interferon on the expression of H-2K, H-2D, and Ia antigens on mouse lymphocytes
O'CONNELL et al. Progressive vaccinia with normal antibodies: a case possibly due to deficient cellular immunity
Boulter Humoral and cellular aspects of the response to infection: Protection against poxviruses
Morishima et al. Local immunity in mumps meningitis
Chantler et al. Rubella-associated arthritis: rescue of rubella virus from peripheral blood lymphocytes two years postvaccination
Chaturvedi et al. Virological study of an epidemic of febrile illness with haemorrhagic manifestations at Kanpur, India, during 1968
Beaman et al. T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure
Crowder et al. Type-specific immunity in pseudomonas diseases
Virgin 4th et al. Role of immune cells in protection against and control of reovirus infection in neonatal mice
Simberkoff et al. Pneumococcal capsuler polysaccharide vaccination in adult chronic hemodialysis patients
Chiba et al. Cell-mediated immune response to mumps virus infection in man
Bhargava et al. Immunogenicity and reactogenicity of indigenously produced MMR vaccine
US20020086022A1 (en) Neutralizing antibody and immunomodulatory enhancing compositions
Philipson et al. Identification of a cytopathogenic agent called U-virus recovered from patients with non-diphtheritic croup and from day-nursery children
Christy et al. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine
Grist Type A7 Coxsackie (type 4 poliomyelitis) virus infection in Scotland
Rammohan et al. Subacute sclerosing panencephalitis after passive immunization and natural measles infection: role of antibody in persistence of measles virus
Ingimarsson et al. Immune Reactions and Long‐Term Therapy with Human Leukocyte Interferon
Hainaut et al. Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event
JP7145863B2 (en) Modified HSV gB protein and HSV vaccine containing same
Freestone The need for new antiviral agents
Howitt A recently isolated strain of poliomyelitic virus
Fogh interferon was also produced during